Phase II open-label study of weekly Taxoprexin (Rm) (DHA-paclitaxel) injection as second line therapy for patients with advanced primary cancers of the liver, including hepatocellular carcinoma (HCC) and carcinoma of the gallbladder or biliary tract (BTC).

Trial Profile

Phase II open-label study of weekly Taxoprexin (Rm) (DHA-paclitaxel) injection as second line therapy for patients with advanced primary cancers of the liver, including hepatocellular carcinoma (HCC) and carcinoma of the gallbladder or biliary tract (BTC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs DHA-paclitaxel (Primary)
  • Indications Biliary cancer; Liver cancer
  • Focus Therapeutic Use
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 08 May 2017 Status changed from completed to discontinued.
    • 12 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jan 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top